论文部分内容阅读
目的:观察恶性腹水行腹水超滤浓缩回输腹腔与香菇多糖腹腔灌注联合治疗的临床效果。方法:收集2014年12月-2015年8月本院治疗的恶性腹水患者120例,根据数字奇偶随机法分为观察组和对照组,每组60例。观察组采用腹水超滤浓缩回输腹腔联合香菇多糖腹腔灌注治疗,对照组采用常规腹腔抽液治疗。比较两组治疗效果与腹围、尿量等变化。结果:观察组治疗有效率为93.33%,明显高于对照组的75.0%(P<0.05);两组治疗后腹围均减小,且观察组减小幅度大于对照组(P<0.05),观察组治疗后24 h尿量多于治疗前(P<0.05);两组治疗后白蛋白(ALB)、和;在肌酐(Cr)水平均降低,TB、血尿素氮(BUN)水平上升,且观察组ALB、Cr水平降低幅度明显大于对照组(P<0.05)。结论:恶性腹水患者行腹水超滤浓缩回输后,再加用香菇多糖腹腔灌注治疗可提高治疗效果,具有较高安全性,可作为治疗恶性腹水的首要方法。
Objective: To observe the clinical effect of combined treatment of malignant ascites by ultrafiltration of ascites and transfusion of peritoneal perfusion of peritoneal cavity with lentinan. Methods: A total of 120 patients with malignant ascites treated in our hospital from December 2014 to August 2015 were collected. The patients were divided into observation group and control group according to the numerical odd and even randomization method, with 60 cases in each group. The observation group was treated with peritoneal ultrafiltration concentrated infusion of trans-abdominal combined with lentinan peritoneal perfusion, the control group using conventional abdominal pumping. Compare the two groups of treatment and abdominal circumference, urine output and other changes. Results: The effective rate of the observation group was 93.33%, which was significantly higher than that of the control group (75.0%, P <0.05). The abdominal circumference of the two groups decreased after treatment, and the reduction rate of the observation group was larger than that of the control group (P <0.05) After 24 hours, the urine output of observation group was higher than that before treatment (P <0.05); albumin (ALB) and the levels of creatinine (Cr), TB and blood urea nitrogen (BUN) The ALB and Cr levels in the observation group were significantly lower than those in the control group (P <0.05). Conclusion: Malignant ascites after pleural effusion ultrafiltration concentration and reinfusion, combined with lentinan peritoneal perfusion therapy can improve the treatment effect, with high safety, as the primary method of treatment of malignant ascites.